医药行业周报：安捷伦将以9.25亿美元收购CDMO公司BIOVECTRA

Investment Ratings - The report does not provide specific ratings for the chemical pharmaceuticals and traditional Chinese medicine industries, while the biopharmaceutical sector is rated as neutral [1][2]. Core Insights - The pharmaceutical sector experienced a decline of 3.24% on July 23, 2024, underperforming the CSI 300 index by 1.11 percentage points, ranking 28th among 31 sub-industries [5]. - Among the sub-industries, pharmaceutical distribution (-1.25%), medical research outsourcing (-2.52%), and medical devices (-2.98%) performed relatively better, while vaccines (-4.89%), other biological products (-4.58%), and blood products (-3.48%) lagged behind [5]. - Notable stock performances included Guoke Hengtai (+20.00%), Kangwei Century (+12.89%), and Fudan Zhanghua (+10.09%) on the gainers' list, while Ruian Gene (-17.98%), Te Bao Biological (-10.00%), and Ailis (-7.47%) were among the biggest losers [5]. Industry News - On July 22, Agilent announced its acquisition of BIOVECTRA for $925 million (approximately 6.728 billion RMB), a Canadian CDMO with capabilities in clinical to commercial scale production of biologics and small molecules. The transaction is expected to complete by 2025 [6][7]. - Shanghai Pharmaceuticals announced that its subsidiary received a drug registration certificate for a new medication, while Lu Kang Pharmaceuticals received approval for a chemical raw material drug [6]. - Microchip Biotech received approval for a clinical trial of a combination therapy for advanced colorectal cancer [6].